Replies to post #62829 on $heff's $tation of $tocks & $olid DD

[$hylo]

APPA.. APF530 targets a $900 million market opportunity in US alone.

Recent competitive setbacks could enhance commercial uptake

Could be second, long-acting, injectable product on market

In 2011, there were 5.1 million vials of injectable 5-HT3 antagonists administered for CINV

The average selling price for market leader Aloxi is $175

APPA held end-of-review meetings with FDA in 1Q 2011

No additional clinical efficacy studies requested

http://www.appharma.com/PDFs/A.P.%20Pharma%20Corporate%20Presentation%20-%20July%202012.pdf